Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.

Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.

Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,

Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.

Andrea Necchi, MD, discusses how results from the CA017-078 trials compares with other perioperative immunotherapy trials in muscle-invasive bladder cancer.

Daniel Heng, MD, discusses final LITESPARK-011 results, including sustained PFS benefit with belzutifan plus lenvatinib vs cabozantinib in advanced ccRCC.

Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.

Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.